Drug profile · INN
lazertinib
LAZCLUZE
lazertinib (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01EB09
Patents linked 0
Pipeline programs 1
News articles 0
Congress events 2
Drug details — lazertinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
lazertinib (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor.
Key facts
INN lazertinib
Brand LAZCLUZE
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EB09
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Congress & event coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lazertinib?
lazertinib (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor.
What is the brand name for lazertinib?
LAZCLUZE is a marketed brand name for lazertinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.